12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb: Phase III data

The double-blind, international Phase III TEACH trial in >3,000 trastuzumab-naïve women who showed no evidence of disease after completing primary neoadjuvant or adjuvant chemotherapy showed that Tykerb monotherapy missed the primary endpoint of significantly reducing the proportion of patients experiencing a DFS event vs. placebo at a median follow-up of 4 years (13% vs. 17%, p=0.053)....

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >